---
title: "Tibet Rhodiola Pharmaceutical Holding Co. (600211.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600211.SH.md"
symbol: "600211.SH"
name: "Tibet Rhodiola Pharmaceutical Holding Co."
industry: "Health Care Distributors"
datetime: "2026-05-20T18:16:02.848Z"
locales:
  - [en](https://longbridge.com/en/quote/600211.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600211.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600211.SH.md)
---

# Tibet Rhodiola Pharmaceutical Holding Co. (600211.SH)

## Company Overview

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.xzyy.cn](https://www.xzyy.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.35)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.34% |  |
| Net Profit YoY | -4.00% |  |
| P/B Ratio | 3.43 |  |
| Dividend Ratio | 2.13% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13383894412.30 |  |
| Revenue | 2998301157.64 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 24.18% | A |
| Profit Margin | 32.32% | A |
| Gross Margin | 92.90% | A |
| Revenue YoY | 6.34% | C |
| Net Profit YoY | -4.00% | C |
| Total Assets YoY | 22.40% | A |
| Net Assets YoY | 2.21% | C |
| Cash Flow Margin | 111.48% | C |
| OCF YoY | 6.34% | C |
| Turnover | 0.52 | C |
| Gearing Ratio | 33.86% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tibet Rhodiola Pharmaceutical Holding Co.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.34%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.43",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.13%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13383894412.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2998301157.64",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "24.18%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "32.32%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "92.90%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "6.34%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.00%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "22.40%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.21%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "111.48%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "6.34%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.86%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.67 | 9/23 | 15.12 | 14.02 | 13.34 |
| PB | 3.39 | 21/23 | 3.86 | 3.65 | 3.30 |
| PS (TTM) | 4.42 | 24/23 | 5.31 | 4.97 | 4.39 |
| Dividend Yield | 2.15% | 11/23 | 4.66% | 4.08% | 3.78% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600211.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600211.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600211.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600211.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**